<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Mixed <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, characterized by low levels of <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>) and high levels of <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, is common in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) and/or <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Dalcetrapib effectively increases <z:chebi fb="0" ids="47775">HDL-C</z:chebi> levels by modulating cholesteryl <z:chebi fb="21" ids="35701">ester</z:chebi> transfer protein (CETP) activity </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this analysis was to investigate the <z:chebi fb="23" ids="18059">lipid</z:chebi> modifying efficacy and safety of dalcetrapib in patients with T2DM and/or <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Post hoc analysis of dalcetrapib therapy in five placebo-controlled, Phase II trials (4-48 weeks of duration) involving T2DM and/or <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, in dyslipidaemic patients with <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> (CHD) or CHD risk equivalent </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Both in patients with and without T2DM and/or <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, dalcetrapib decreased CETP activity by 26-58% and increased <z:chebi fb="0" ids="47775">HDL-C</z:chebi> levels by 23-34%, depending on dose and duration of treatment </plain></SENT>
<SENT sid="5" pm="."><plain>Dalcetrapib did not significantly affect <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>) or <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B levels </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment with dalcetrapib was generally well tolerated with a similar number of adverse events reported between patient groups and between those receiving dalcetrapib compared with placebo </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Dalcetrapib similarly decreased CETP activity and increased <z:chebi fb="0" ids="47775">HDL-C</z:chebi> levels in patients with and without T2DM or <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>; the ongoing Phase III dal-OUTCOMES study will help to determine if dalcetrapib's improvement in <z:chebi fb="23" ids="18059">lipid</z:chebi> levels also reduces <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality </plain></SENT>
</text></document>